editora
recent
trial
investig
use
glucocorticosteroid
prednisolon
therapi
reduct
sever
dengu
diseas
mani
pathogen
induc
acceler
excess
inflamm
result
detriment
rather
protect
effect
dengu
viru
wellcharacter
exampl
phenomenon
sever
solubl
mediat
innat
inflammatori
respons
link
sever
patholog
howev
studi
larg
correl
fail
elucid
molecular
mechan
facilit
specif
patholog
nevertheless
continu
observ
excess
inflamm
concurr
drop
viremia
develop
sever
symptom
prompt
sever
previou
attempt
immunosuppress
strategi
mean
reduc
sever
dengu
diseas
enhanc
diseas
due
suppress
innat
antivir
mechan
primari
concern
studi
tam
et
al
reveal
neither
protect
effect
discuss
prof
barrett
enhanc
diseas
result
surpris
seem
like
glucocorticosteroid
treatment
would
prove
either
product
ie
reduc
excess
inflamm
result
sever
symptom
detriment
ie
reduc
innat
mediat
viral
clearanc
greater
incid
sever
diseas
would
note
data
may
explain
glucocorticosteroid
treatment
fail
affect
present
sever
dengu
investig
dexamethason
dengu
therapeut
primari
monocytederiv
macrophag
denguena
donor
sampl
collect
cytokin
viral
titer
measur
day
note
interest
phenomenon
believ
complement
result
obtain
patient
figur
observ
signific
mannwhitney
u
decreas
viral
load
day
dexamethason
treatment
concomit
decreas
still
elev
level
select
inflammatori
cytokin
rant
tumor
necrosi
factor
interferon
interleukin
interleukin
interleukin
granulocyt
colonystimul
factor
monocyt
chemoattract
protein
day
suppress
cytokin
still
evid
viral
titer
rebound
level
untreat
sampl
viral
titer
dexamethasonetr
sampl
exceed
untreat
sampl
day
day
presum
inflammatori
respons
remain
suffici
intact
prevent
enhanc
viral
load
find
implic
use
immunosuppress
therapi
dengu
diseas
manifest
excess
immun
activ
eg
avian
influenza
sever
acut
respiratori
syndrom
coronaviru
although
drug
capabl
reduc
inflammatori
mediat
import
target
infect
tissu
macrophag
system
effect
relat
sever
patholog
may
affect
altern
effect
treatment
may
depend
critic
time
drug
administr
immedi
treatment
follow
infect
may
abl
help
direct
develop
immun
respons
effect
viral
clearanc
prevent
sever
symptom
subset
patient
risk
shock
hemorrhag
howev
unrealist
option
clinic
set
suggest
modest
immunosuppress
may
safe
use
diseas
adjunct
therapi
coordin
directact
antivir
capabl
reduc
pathogen
load
effici
futur
experi
investig
strategi
may
unlock
therapeut
potenti
otherwis
nonviabl
option
figur
dengu
viru
titer
kinet
primari
monocytederiv
macrophag
donor
absenc
black
bar
presenc
gray
bar
dexamethason
determin
llcmk
plaqu
assay
bk
equival
kinet
assess
cytokin
chemokin
conduct
perform
custom
bioplex
multiplex
analysi
luminex
analyz
error
bar
repres
standard
error
signific
assess
mannwhitney
u
nonparametr
test
owe
failur
leven
test
homogen
xaxi
valu
repres
day
infect
day
abbrevi
gcsf
granulocyt
colonystimul
factor
interferon
interleukin
interleukin
interleukin
interleukin
monocyt
chemoattract
protein
mif
macrophag
migrat
inhibitori
factor
pfu
plaqueform
unit
tumor
necrosi
factor
clinic
infecti
diseas
author
publish
oxford
univers
press
behalf
infecti
diseas
societi
america
open
access
articl
distribut
term
creativ
common
attribut
licens
http
creativecommon
permit
unrestrict
reus
distribut
reproduct
medium
provid
origin
work
properli
cite
doi
